{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098994","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.858257+00:00","generated_at":"2026-05-17T03:50:56.909362+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Traws Pharma doses first subject in Phase 2 COVID study of ratutrelvir; top-line data by year-end 2025","bullets":["First subject dosed in Phase 2 study of ratutrelvir, a ritonavir-free anti-viral for newly diagnosed COVID.","Two trials: non-inferiority versus PAXLOVID and a single-arm study for PAXLOVID-ineligible patients.","Top-line results from both Phase 2 studies expected by year-end 2025.","Ratutrelvir is once-daily, single tablet for 10 days; aims to reduce rebound and Long COVID risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098994","json":"https://secwatch.observer/filing/0001104659-25-098994.json","markdown":"https://secwatch.observer/filing/0001104659-25-098994.md","text":"https://secwatch.observer/filing/0001104659-25-098994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/0001104659-25-098994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/tm2528641d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:50:56.909362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}